EUVIMEDEUVIMED entdecken
Crossref

Silencing APLNR enhances the radiosensitivity of prostate cancer by modulating the PI3K/AKT/mTOR signaling pathway

Peng Li, Yanfang Cui, Keyao Hu, Xiaofei Wang, Yizhi Yu

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03692-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Peng Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yantaishan Hospital, Laishan District Science and Technology Avenue 10087, Yantai, 264003, Shandong, People's Republic of Chin…. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Prostatic Neoplasms, Signal Transduction, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aberrant expression of apelin receptor (APLNR) has been found to be involved in various cancers' development, however, its function in prostate cancer (PCa) remains unclear. The research aimed to investigate the role and potential mechanism of APLNR in PCa. METHODS: The mRNA expression of APLNR was detected via qRT-PCR assay. PCa cell proliferation and apoptosis were determined through plate cloning and flow cytometry. In addition, the expression of apoptosis-related proteins (Bax, Bcl-2, and cleaved caspase-3) was evaluated using western blot. DNA damage marker (γ-H2AX) was analyzed by immunofluorescence and western blot. GSEA analysis was performed for seeking enrichment pathways of APLNR in PCa, and the protein levels of PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR were tested using western blot. RESULTS: APLNR expression was up-regulated in PCa tissues and cells. Silencing APLNR enhanced the sensitivity of PCa cells to radiotherapy, which was manifested by inhibiting cell proliferation, promoting cell apoptosis, and promoting DNA damage. Next, silencing APLNR inhibited the PI3K/AKT/mTOR pathway. Specifically, 740Y-P (the PI3K/AKT/mTOR pathway activator) reversed the effects of silencing APLNR on PCa cell proliferation, apoptosis and DNA damage. CONCLUSION: Silencing APLNR inhibited cell proliferation, promoted cell apoptosis, and enhanced the radiosensitivity of PCa cells, which was involved in the PI3K/AKT/mTOR signaling pathway. This study is conducive to the deeper understanding of PCa and further provides a new perspective for the treatment of PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesProstatic NeoplasmsSignal TransductionProto-Oncogene Proteins c-aktRadiation TolerancePhosphatidylinositol 3-KinasesApelin ReceptorsHumansMaleApoptosisCell ProliferationGene SilencingCell Line, TumorDNA Damage

Stichwörter der Autor:innen

APLNRCell apoptosisPI3K/AKT/mTOR signaling pathwayProstate cancer

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR protein, humanPhosphatidylinositol 3-KinasesApelin Receptors

Autor:innen und Institutionen

  • Department of Urology, Yantaishan Hospital, Laishan District Science and Technology Avenue 10087, Yantai, 264003, Shandong, People's Republic of China.
  • Department of Ultrasonography, Yantaishan Hospital, Yantai, 264003, Shandong, People's Republic of China.
  • Department of Urology, Yantaishan Hospital, Laishan District Science and Technology Avenue 10087, Yantai, 264003, Shandong, People's Republic of China. yzy7209@hotmail.com.

Zitieren

APA

Li, P., Cui, Y., Hu, K., Wang, X., & Yu, Y. (2024). Silencing APLNR enhances the radiosensitivity of prostate cancer by modulating the PI3K/AKT/mTOR signaling pathway. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03692-1

Vancouver

Li P, Cui Y, Hu K, Wang X, Yu Y. Silencing APLNR enhances the radiosensitivity of prostate cancer by modulating the PI3K/AKT/mTOR signaling pathway. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03692-1

BibTeX
@article{Li2024,
  author = {Li, Peng and Cui, Yanfang and Hu, Keyao and Wang, Xiaofei and Yu, Yizhi},
  title = {Silencing APLNR enhances the radiosensitivity of prostate cancer by modulating the PI3K/AKT/mTOR signaling pathway},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03692-1}
}
Kostenlos starten →